Titan’s Probuphine helps battle opioid addiction

Titan Pharmaceuticals

The CBS affiliate in Pittsburgh, KDKA-TV has produced a segment on the benefits of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant of buprenorphine for the maintenance treatment of opioid addiction.

Dr. Frank Kunkel, of Accessible Recovery Services, says relapse rates while patients are on the Probuphine implant are low compared to other similar medications.

The segment also quotes a Probuphine patient, who says that by having the implant, the cravings and desire to use were eliminated.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.